34 completed. 34 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Completed 34 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 1 | Completed 1 |
Follow Panuveitis: new trials by email Literature Review of Panuveitis trials Research Report on Panuveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dusquetide for the Treatment of Behcet's Disease Dusquetide - Behçet Disease | Phase 2 | Completed | Soligenix | 8 | 2024-11-18 | 2026-08-26 |
| Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome Ustekinumab 90 mg - Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome | Phase 2 | Completed | Liu Tian | 8 | 2024-03-24 | 2026-05-13 |
| Upadacitinib for Refractory Behcet's Syndrome Upadacitinib 15 MG - Behcet Syndrome | Phase 2 | Completed | Liu Tian | 27 | 2024-01-25 | 2025-12-02 |
| A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Prednisolone acetate - Anterior Uveitis | Phase 2 | Completed | VivaVision Biotech, Inc | 89 | 2023-11-27 | 2025-01-27 |
| Low-dose IL-2 Treatment on Behcet's Disease Low-dose IL-2, Placebo - Behcet's Disease | Phase 2 | Completed | HeJing | 60 | 2021-10-12 | 2024-04-03 |
| ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study) ACTH gel - Uveitis | Phase 2 | Completed | Quan Dong Nguyen | 28 | 2017-11-10 | 2025-12-17 |
| Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Subcutaneous Ustekinumab - Behçet Disease | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 16 | 2017-06-14 | 2025-09-08 |
| Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Ustekinumab - Uveitis | Phase 2 | Completed | National Eye Institute (NEI) | 8 | 2017-03-30 | 2021-03-26 |
| 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement Canakinumab - Behcet Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 8 | 2016-06-23 | 2020-06-11 |
| Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis LME636 60 mg/mL ophthalmic solution, Dexamethasone 0.1% ophthalmic solution, LME636 Vehicle - Acute Anterior Uveitis | Phase 2 | Completed | Alcon Research | 45 | 2015-07-17 | 2018-07-02 |
| A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis NS2, Prednisolone acetate ophthalmic suspension (1%) - Non-infectious Anterior Uveitis | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 45 | 2015-03-01 | 2023-03-27 |
| Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis 8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops - Non-Infectious Anterior Uveitis | Phase 1 / Phase 2 | Completed | Aciont Inc | 44 | 2014-10-01 | 2017-04-27 |
| Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis 4 mg CLS-TA, 0.8 mg CLS-TA - Uveitis, Macular Edema | Phase 2 | Completed | Clearside Biomedical, Inc. | 22 | 2014-10-01 | 2021-02-08 |
| Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Interleukin 2 - Rheumatoid Arthritis, Ankylosing Spondylitis | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 81 | 2014-01-06 | 2021-07-20 |
| Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 11 | 2013-02-01 | 2021-02-21 |
| Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Intravitreal Infliximab - Behçet's Disease, Uveitis | Phase 1 / Phase 2 | Completed | Cairo University | 20 | 2013-01-01 | 2015-12-03 |
| Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , LFG316, Conventional Therapy - Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis | Phase 2 | Completed | Novartis Pharmaceuticals | 25 | 2012-12-20 | 2021-01-05 |
| Anakinra for Behcet s Disease Anakinra - Autoimmune Connective Tissue Disorder, Immune System Diseases | Phase 1 / Phase 2 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 6 | 2011-09-01 | 2017-05-12 |
| Topical Interferon Gamma for Macular Edema Secondary to Uveitis Interferon Gamma-1b - Anterior Uveitis, Uveitis | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 5 | 2011-06-01 | 2012-10-08 |
| A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Apremilast (CC-10004), Placebo - Behcet Syndrome | Phase 2 | Completed | Amgen | 111 | 2009-08-01 | 2020-06-19 |
Showing 20 of 34. Sign in to see all of them.
Uveitis (16) · Behcet Syndrome (15) · Uveitis, Anterior (10) · Uveitis, Posterior (9) · Uveitis, Intermediate (7) · Macular Edema (5) · Inflammation (3) · Retinal Vasculitis (3) · Birdshot Chorioretinopathy (2) · Choroidal Effusions (2) · Ophthalmia, Sympathetic (2) · Retinal Diseases (2) · Aortic Arch Syndromes (1) · Arthritis (1)
Eye Diseases (34) · Uveal Diseases (34) · Uveitis (18) · Cardiovascular Diseases (17) · Skin and Connective Tissue Diseases (17) · Vascular Diseases (17) · Skin Diseases (16) · Skin Diseases, Vascular (16) · Vasculitis (16) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Genetic Diseases, Inborn (15) · Hereditary Autoinflammatory Diseases (15) · Mouth Diseases (15) · Skin Diseases, Genetic (15)
Daclizumab (3) · prednisolone acetate (3) · Dexamethasone (2) · Interleukin-2 (2) · Ophthalmic Solutions (2) · Ustekinumab (2) · Adrenal Cortex Hormones (1) · Adrenocorticotropic Hormone (1) · Colchicine (1) · Cyclophosphamide (1) · ESBA105 (1) · Interferon alpha-2 (1) · Interferon-alpha (1) · Interleukin 1 Receptor Antagonist Protein (1) · Prednisone (1)
National Eye Institute (NEI) (5) · Assistance Publique - Hôpitaux de Paris (3) · Novartis Pharmaceuticals (3) · Allergan (2) · Clearside Biomedical, Inc. (2) · Liu Tian (2) · Tehran University of Medical Sciences (2) · Aciont Inc (1) · Alcon Research (1) · Aldeyra Therapeutics, Inc. (1) · Amgen (1) · Cairo University (1) · ESBATech AG (1) · Eyegate Pharmaceuticals, Inc. (1) · HeJing (1)
United States (18) · China (4) · France (4) · Turkey (Türkiye) (4) · Germany (3) · India (2) · Iran (2) · United Kingdom (2) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · Czechia (1) · Greece (1) · Israel (1)
Bahar Sadeghi, MD (2) · Thomas Ciulla, MD (2) · Ahmet Gul, MD (1) · Arash Tehrani Banihashemi, MD, MPH (1) · Ayhan Dinc, MD (1) · C. Stephen Foster, MD (1) · C.Stephen Foster, MD, FACS, FACR (1) · Cem Mat, MD (1) · Cengiz Korkmaz, MD (1) · Cheyda Chams-Davatchi, MD (1)
PMID 15079763, PMID 17353400, PMID 19268890, PMID 19597921, PMID 19664754, PMID 19717547, PMID 20212194, PMID 20212197, PMID 20704622, PMID 20926833, PMID 21220619, PMID 23411886, PMID 23761087, PMID 25638011, PMID 25875256, PMID 27980877, PMID 28335798, PMID 30472651, PMID 32955967, PMID 34864108, PMID 37316690, PMID 38782788, PMID 41400947
R44EY014772 (1)